JUNJIE PIAO

Dr. JUNJIE PIAO

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2024 in Apoptosis
Verified
Journal Article
Closed access
PDF file
ZSZhennv Shen
Zhennv Shen
LZLei Zhao
Lei Zhao
SYSeung-Ah Yoo
Seung-Ah Yoo
ZLZhenhua Lin
Zhenhua Lin
YZYu Zhang
Yu Zhang
JPJUNJIE PIAO
JUNJIE PIAO

1 July 2019 in Cancer Letters
Verified
Journal Article
Open access
YYYang Yang
Yang Yang
GZGuang Zhu
Guang Zhu
BDBing Dong
Bing Dong
JPJUNJIE PIAO
JUNJIE PIAO
LCLiyan Chen
Liyan Chen
ZLZhenhua Lin
Zhenhua Lin
Overexpression of NQO1 is associated with poor prognosis in human cancers including lung, stomach, colon, cervical, and pancreatic cancers. However, the molecular mechanisms underlying the protumorigenic capacities of NQO1 have not been fully elucidated. Here, we investigated this question and determined the molecular mechanisms underlying the roles of NQO1 in glycolysis reprogramming, proliferation, and metastasis breast cancer (BC) cells. The results indicated that NQO1 overexpression in BC cells raises glucose metabolism and metastasis related behaviors. Mechanistically, NQO1 bound to PKLR, activated the AMPK and AKT/mTOR signaling pathway and consequently induced glycolytic reprogramming. In addition, 2-deoxy-d-glucose (2-DG) or 3-bromopyruvate (3-BrPA) influenced proliferation and regulated the expression of genes involved in the epithelial-to-mesenchymal transition (EMT) by restraining glycolytic reprogramming. Finally, overexpression of NQO1 and PKLR in human BC tissues was remarkably related to lymph node (LN) metastasis and poor prognosis. Together, these results demonstrate that the NQO1/PKLR axis can promote the progression of BC by modulating glycolytic reprogramming and suggest that targeting NQO1 and its downstream effectors are promising therapeutic targets for preventing the BC progression.

11 January 2024 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
LZLei Zhao
Lei Zhao
HMHui Miao
Hui Miao
MQMingqi Quan
Mingqi Quan
SWShuhao Wang
Shuhao Wang
YZYu Zhang
Yu Zhang
JPJUNJIE PIAO
JUNJIE PIAO

2 December 2021 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
XCXuelian Cui
Xuelian Cui
YWYixuan Wang
Yixuan Wang
WLWeiqiang Lan
Weiqiang Lan
SWShuhao Wang
Shuhao Wang
YCYing Cui
Ying Cui
JPJUNJIE PIAO
JUNJIE PIAO

1 July 2019 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
CQChunji Quan
Chunji Quan
JSJie Sun
Jie Sun
ZLZhenhua Lin
Zhenhua Lin
TJTiefieng Jin
Tiefieng Jin
BDBing Dong
Bing Dong
JPJUNJIE PIAO
JUNJIE PIAO
Background: Ezrin and YAP are abnormally expressed in various cancers, and play pivotal roles in cancer initiation and development. However, the mechanisms of Ezrin in pancreatic cancer have not been fully elucidated. In this study, we aimed to elucidate the functions and mechanisms of Ezrin in the pathogenesis of pancreatic cancer. Methods: Effects of Ezrin deregulation on pancreatic cancer phenotype were determined in Capan-1 and BxPC-3 cells using MTT, colony formation, transwell, wound-healing, and chick chorioallantoic membrane assays. To find out the underlying mechanism of Ezrin, multiple assays were performed to detect the effect of Ezrin on Akt pathway activation and YAP expression. Then, Ezrin and YAP expression was analyzed in pancreatic cancer and normal pancreas samples. Finally, the prognostic value of Ezrin and YAP was evaluated in pancreatic cancer patients. Results: Ezrin promoted proliferation, invasion, epithelial–mesenchymal transition (EMT) progression, and angiogenesis of pancreatic cancers. Mechanistically, Ezrin activated Akt/mTOR pathways and induced YAP phosphorylation and nucleus translocation. The PI3K/Akt pathway inhibitor, rapamycin, and LY294002 could partially attenuate the effect of Ezrin on cell proliferation, invasion, EMT progression, and YAP phosphorylation and translocation. Moreover, both Ezrin and YAP were significantly overexpressed in pancreatic cancer tissues compared with adjacent normal pancreas, and correlated with poor prognosis in pancreatic cancer patients. Multivariate survival analysis showed that Ezrin was an independent prognostic marker for pancreatic cancer. Furthermore, the expression status of Ezrin and YAP had positive correlations in pancreatic cancer tissues. Conclusion: Ezrin promoted pancreatic cancer proliferation, invasion, migration, and EMT progression, partially through activating the PI3K/Akt pathway, and also regulated YAP phosphorylation and translocation, partially through the PI3K/Akt pathway. Ezrin and YAP were significantly overexpressed in pancreatic cancers, and correlated with poor prognosis in pancreatic cancer patients.

1 June 2017 in Human Pathology
Verified
Journal Article
Closed access
XCXuelian Cui
Xuelian Cui
ZLZhenling Li
Zhenling Li
JPJUNJIE PIAO
JUNJIE PIAO
JLJinzi Li
Jinzi Li
LLLongshan Li
Longshan Li
AJAihua Jin
Aihua Jin